S&P 500
(-0.34%) 5 018.39 points
Dow Jones
(0.23%) 37 903 points
Nasdaq
(-0.33%) 15 605 points
Oil
(0.09%) $79.07
Gas
(0.31%) $1.938
Gold
(0.89%) $2 331.60
Silver
(0.77%) $26.96
Platinum
(1.13%) $965.70
USD/EUR
(0.00%) $0.933
USD/NOK
(-0.04%) $11.03
USD/GBP
(-0.09%) $0.798
USD/RUB
(0.06%) $93.51

实时更新: Dermata Therapeutics, [DRMA]

交易所: NASDAQ 部门: Healthcare 工业: Biotechnology
最后更新时间2 May 2024 @ 04:00

0.15% $ 0.333

Live Chart Being Loaded With Signals

Commentary (2 May 2024 @ 04:00):
Profile picture for Dermata Therapeutics, Inc.

Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions...

Stats
今日成交量 6 886.00
平均成交量 126 947
市值 2.21M
EPS $0 ( 2024-02-20 )
下一个收益日期 ( $-0.360 ) 2024-05-09
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -0.120
ATR14 $0.00400 (1.20%)
Insider Trading
Date Person Action Amount type
2024-01-04 Mento Steven J Buy 10 000 Stock Option (Right to Buy)
2024-01-04 Proehl Gerald T Buy 125 000 Stock Option (right to buy)
2024-01-04 Fisher Mary Buy 10 000 Stock Option (Right to Buy)
2024-01-04 Scott Kathleen D. Buy 10 000 Stock Option (Right to Buy)
2024-01-04 Sandler Andrew Seth Buy 10 000 Stock Option (Right to Buy)
INSIDER POWER
100.00
Last 98 transactions
Buy: 8 169 572 | Sell: 872 238

Dermata Therapeutics, 相关性

10 最正相关
SVAC0.964
PAIC0.955
TLGT0.926
SVOK0.917
RMRM0.917
SPRT0.885
EARS0.875
PROG0.873
BLPH0.863
FORE0.859
10 最负相关
NETE-0.977
AMRB-0.924
MMAC-0.903
RAVN-0.892
SRAC-0.88
ANIK-0.866
BOCH-0.85
ATHN-0.849
CPTN-0.839
ODT-0.835

你知道吗?

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。

相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Dermata Therapeutics, 财务报表

Annual 2023
营收: $0
毛利润: $0 (0.00 %)
EPS: $-2.67
FY 2023
营收: $0
毛利润: $0 (0.00 %)
EPS: $-2.67
FY 2022
营收: $0
毛利润: $0 (0.00 %)
EPS: $-13.92
FY 2021
营收: $0.00
毛利润: $0.00 (0.00 %)
EPS: $-2.43

Financial Reports:

No articles found.

Dermata Therapeutics,

Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of hyperhidrosis and aesthetic conditions. The company was incorporated in 2014 and is headquartered in San Diego, California.

关于 实时信号

此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。

实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。